New positive pivotal phase 3 study data released on oral weekly risperidone for schizophrenia.
Drug Watch
Latest News
Advertisement
CME Content
Advertisement
The data assess the extended efficacy of the treatment for up to 4 years.
The device is now available at 2 US clinics, with training and installation currently underway at several other locations.
The device is currently under clinical trial investigation as an adjunct treatment to standard of care therapy for experiential negative symptoms of schizophrenia.
New study results show evenamide as an add-on to antipsychotics for treatment-resistant schizophrenia significantly reduced disease severity.
Initial data from phase 2 safety profile for psilocybin in the treatment of PTSD indicates the treatment is well-tolerated.
Advertisement
Advertisement
Trending on Psychiatric Times
1
New 6-Month Data From Second Phase 3 Trial Confirms Rapid Effect of COMP360 for TRD
2
Filling the Gap Between IV Ketamine Clinical Use and Evidence-Based Standards
3
Phase 2 Trial Initiated for Briumvi for Treatment-Resistant Schizophrenia
4
Developments in Cannabis Withdrawal and Addiction Treatment
5